Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — FY2009 Earnings Presentation
16 slides from Novo Nordisk A/s Class B's earnings presentation, February 2010
Slide 1: Investor conference call Full-year 2009
Investor presentation Investor conference call Full-year 2009
Slide 2: Agenda
Investor presentation Full-year 2009 Slide no 2 Agenda • Introduction (Lars Rebien Sørensen, CEO) • Sales update (Lars Rebien Sørensen, CEO) • Pipeline update (Mads Krogsgaard Thomsen, CSO) • Financial results and outlook (Jesper Brandgaard, CFO) • Questions & answers session
Slide 3: Forward-looking statements
Investor presentation Full-year 2009 Slide no 3 Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document as well as the company’s Annual Report 2009 and Form 20-F, both filed with the SEC in February 2010, a
Slide 4: Highlights and key events
Investor presentation Full-year 2009 Slide no 4 Highlights and key events Market development • Robust sales growth: +12% (+11% in local currencies) • Sales growth driven by modern insulins: +24% (+23%) • North America sales growth: +21% (+15%) • International Operations sales growth: +17% (+19%) Res
Slide 5: Key products continue to drive growth
Investor presentation Full-year 2009 Slide no 5 Key products continue to drive growth – full year 2009 Sales as reported Growth analysis HRT Local currencies Growth Share of Norditropin® +8% growth +14% 3% 9% Diabetes care Modern insulins 23% 82% NovoSeven® +12% Human insulins -5% -13% +11% 14% Prot
Slide 6: North America drives sales growth
Investor presentation Full-year 2009 Slide no 6 North America drives sales growth - full year 2009 Sales as reported Growth analysis Japan & Oceania +14% North America Local currencies Growth Share of +21% growth 11% International North America 15% 48% Operations +17% Europe 5% 19% 19% 36% Internati
Slide 7: Continued conversion to modern insulins drives value creation on the insulin market
Investor presentation Full-year 2009 Slide no 7 Continued conversion to modern insulins drives value creation on the insulin market Modern insulin penetration Modern insulin market shares Novo Nordisk Sanofi-Aventis Eli Lilly 70% 60% 59% 50% 45% 32% Modern insulin 40% 34% 30% 20% 20% Human insulin 1
Slide 8: Solid progress of Victoza roll-out
Investor presentation Full-year 2009 Slide no 8 Solid progress of Victoza® roll-out Diabetes market share in Germany (value) Global roll-out continues Victoza® Exenatide GLP-1 all 4% • Launched in Germany, UK, Denmark, Diabetes market share (value) Ireland, Norway, Greece, Sweden, The 3.1% Netherlan
Slide 9: R&D pipeline: Diabetes and obesity
Investor presentation Full-year 2009 Slide no 9 R&D pipeline: Diabetes and obesity Compound Type Indication Status (phase) 1 2 3 Filed Appr. Victoza® Once-daily GLP-1 analogue Type 2 Degludec* Ultra LA basal insulin Type 1+2 DegludecPlus* Ultra LA basal insulin with a bolus boost Type 1+2 Semaglutid
Slide 10: R&D pipeline: Haemostasis
Investor presentation Full-year 2009 Slide no 10 R&D pipeline: Haemostasis Compound Type Indication Status (phase) 1 2 3 Filed Appr. NovoSeven® RT rFVIIa Haemophilia w. inhibitors NN1841 rFXIII Congenital FXIII deficiency NN7008 rFVIII Haemophilia A NN1731 FA rFVIIa analogue Haemophilia w. inhibitor
Slide 11: R&D pipeline: Other biopharmaceuticals
Investor presentation Full-year 2009 Slide no 11 R&D pipeline: Other biopharmaceuticals Compound Type Indication Phase 1 2 3 Filed Appr. NN8630 LA hGH GHD & AGHD Vagifem® Low Dose Topical product Menopausal symptoms Anti-IL20 Monoclonal antibody PSA / RA Anti-C5aR Monoclonal antibody RA NN8555 Monoc
Slide 12: Financial results
Investor presentation Full-year 2009 Slide no 12 Financial results DKK million 2009 2008 change Sales 51,078 45,553 12% Gross profit 40,640 35,444 15% Gross margin 79.6% 77.8% Sales and distribution costs 15,420 12,866 20% Percent of sales 30.2% 28.2% Research and development costs 7,864 7,856 0% Pe
Slide 13: Cash return to shareholders
Investor presentation Full-year 2009 Slide no 13 Cash return to shareholders Dividend and payout ratio Share repurchase programme Dividend (DKK) Payout ratio DKK billion Dividend proposed for 2009 8 8 45% DKK 19 billion 7.5 Dividend 7 7 6.5 Payout ratio 40% 6 6 5 5 4.8 4.7 35% 4 4 30% 3.0 3 3 2 2 25
Slide 14: Currency development – key currencies
Investor presentation Full-year 2009 Slide no 14 Currency development – key currencies close to 2009 average Annual impact on operating 650 profit of a 5% movement in Spot rates Quarterly average Annual average currency (DKK million) 2010 USD/DKK 600 USD 580 CNY 100 550 JPY 150 GBP 80 500 CAD 40 450
Slide 15: Financial guidance for 2010
Investor presentation Full-year 2009 Slide no 15 Financial guidance for 2010 Key currency rates • Sales growth expectations: DKK 2009 2010 Current per 100 average average* rate* • 6-10% in local currencies USD 536 528 529 • Reported at a similar level as in local currencies JPY 5.73 5.88 5.91 • Oper
Slide 16: Investor information
Investor presentation Full-year 2009 Slide no 16 Investor information Share information Investor Relations Novo Nordisk’s B shares are listed contacts on the stock exchange in Novo Nordisk A/S Investor Relations Copenhagen. Its ADRs are listed on Novo Allé, DK-2880 Bagsværd the New York Stock Exchan